Relationship between a concentration of lipoprotein-associated secretory phospholipase A2 and markers of subclinical atherosclerotic lesion of arterial wall in patients with low and moderate risk by SCORE scale


Cite item

Full Text

Abstract

Aim. To show relations between a concentration of lipoprotein-associated secretory phospholipase A2 (LPPLa2) and markers of subclinical atherosclerotic lesion of the arterial wall in patients with low and moderate risk by the SCORE scale.
Material and methods. A total of 378 individuals with low and moderate risk of atherosclerotic lesion of the arterial wall (285 females, 93 males) were divided into groups by 1) age and sex, 2) number of atherosclerotic plaques (ASP) in the carotid arteries: 0ASP (n = 158), ASP (n = 61), more than one ASP (n = 159); 3) plaque characteristics: homogeneous (n = 31), heterogenous (n = 189), 4) the presence of ASP in CA and level of LPPLa2 in the blood (with high content - n = 137, with normal content - n = 83). Duplex CA scanning was made to estimate intima-media thickness (IMT), to detect AP in the CA. Computer sphygmography estimated velocity of the pulse wave (PWV) from the carotid to femoral artery. Normal values of IMT and PWV were estimated individually with reference to gender and age. LPPLa2 was measured immunoturbodimetrically using diagnostic kits (PLAC Test Elisa Kit, diaDexus, USA), shreshold value < 200 ng/ml.
Results. LPPLa2 content medians in different age groups in males and females differed insignificantly. LPPLa2 concentration in the groups of patients regarding ASP in CA was elevated in relation to the threshold value (200 ng/ml) in all the groups but did not significantly differ: 216 (179-257) ng/ml in the group 0ASP, 226 (190-274) ng/ml - in the group of patients 1ASP and 212 (174-254) ng/ml - in the group of patients more than one ASP (p > 0.05). In the groups with homogeneous and heterogenous ASP significant differencies were neither between the medians nor between frequency of deviation from normal (p = 0.28). 25.5% patients from the group with an elevated level of LPPLa2 had ASP with a hypoechogenic component.
Conclusion. No significant correlation was revealed between concentration of LPPLa2, IMT PWV, number of ASP and carotid stenosis.

About the authors

Saule Zhaksylykovna Urazalina

Email: surazalina@mail.ru

Vladimir Nikolaevich Titov

Tat'yana Nikolaevna Vlasik

Tat'yana Valentinovna Balakhonova

Yuriy Aleksandrovich Karpov

Valeriy Vladimirovich Kukharchuk

S A Boytsov

S G Urazalina

Russian Cardiological Research Center, Moscow

Russian Cardiological Research Center, Moscow

V N Titov

Russian Cardiological Research Center, Moscow

Russian Cardiological Research Center, Moscow

T N Vlasik

Russian Cardiological Research Center, Moscow

Russian Cardiological Research Center, Moscow

T V Balakhonova

Russian Cardiological Research Center, Moscow

Russian Cardiological Research Center, Moscow

Yu A Karpov

Russian Cardiological Research Center, Moscow

Russian Cardiological Research Center, Moscow

V V Kukharchuk

Russian Cardiological Research Center, Moscow

Russian Cardiological Research Center, Moscow

S A Boitsov

Russian Cardiological Research Center, Moscow

Russian Cardiological Research Center, Moscow

References

  1. Schaloscke R., Dennis E. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta 2006; 1761: 1246-1259.
  2. Suckling K. E., Macphee C. H. Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque. Expert Opin. Ther. Targets 2002; 6 (3): 309-314.
  3. Zalewski A., Nelson J. J., Hegg L., Macphee C. H. Lp-PLA2: a new kid on the block. Clin. Chem. 2006; 52 (9): 1645-1650.
  4. Virani S. S., Nambi V. The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis. Curr. Atheroscler. Rep. 2007; 9 (2): 97-103.
  5. Corson M. A., Jones P. H., Davidson M. H. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J. Cardiol. 2008; 101 (12A): 41F-50F.
  6. Lerman A., McConnell J. P. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor? Am. J. Cardiol. 2008; 101 (12A): 11F-22F.
  7. Anderson J. L. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am. J. Cardiol. 2008; 101 (12A): 23F-33F.
  8. Gerber Y., McConnell J. P., Jaffe A. S. et al. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler. Thromb. Vase. Biol. 2006; 26: 2517-2522.
  9. Gorelick P. B. Lipoprotein-associated phospholipase A2 and risk of stroke. Am. J. Cardiol. 2008; 101 (12A): 34F-40F.
  10. Lp-PLA(2) Studies Collaboration, Thompson A., Gao P. et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375: 1536-1544.
  11. Brilakis E. S., Khera A., McGuire D. K. et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis 2008; 199: 110-115.
  12. Persson M., Nilsson J. A., Nelson J. J. et al. The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 2007; 190: 388-396.
  13. Ballantyne C. M., Hoogeveen R. C., Bang H. et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-841.
  14. Davidson M. H., Corson M. A., Alberts M. J. et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am. J. Cardiol. 2008; 101: 51F-57F.
  15. Tegos T. J., Sohail M., Sabetai M. M. et al. Echomorphologic and histopathologic characteristics of unstable carotid plagues. Am. J. Neuroradiol. 2000; 21: 1937-1944.
  16. Greenland P., Alpert J. S., Beller G. A. et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Cardiovascular Magnetic Resonance Society of Cardiovascular Computed Tomography, and Society for and Prevention, Society for Cardiovascular Angiography and Interventions, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging Developed in Collaboration With the American Society of Echocardiography, Foundation/American Heart Association Task Force on Practice Guidelines Asymptomatic Adults: A Report of the American College of Cardiology. J. Am. Coll. Cardiol. 2010; 56: e50-e103.
  17. Stein J. I., Korcarz C. E. et al. American Society of Echocardiography Carotid Intima-Media Thickness Task Force. J. Am. Soc. Echocardiogr. 2008; 21: 93-111.
  18. Милягин В. А. и др. Новый автоматизированный метод определения скорости распространения пульсовой волны. Функцион. диагн. 2004; 1: 33-39.
  19. Miyra S., Maki N., Byrd W. et al. The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma. Lipids 1991; 26: 1015-1020.
  20. Blake G. J., Dada N., Fox J. C. et al. A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J. Am. Coll. Cardiol. 2001; 38: 1302-1306.
  21. Koenig W., Khuseyinova N., Löwel H. et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population. Results from the 14-year follow-up of a large cohort from Southern Germany. Circulation 2004; 110: 1903-1908.
  22. Nambi V., Hoogeveen R. C. et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2009; 40 (2): 376- 381.
  23. Pearson T. A., Mensah G. A., Wayne A. R. et al. Markers of inflammation and cardiovascular disease application to clinical and public health practice. A statement for Healthcare professionals from the Centers for disease control and prevention and the American Heart association. Circulation 2003; 107: 499-511.
  24. Kiortsis D. N., Tsouli S., Lourida E. S. et al. Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology 2005; 56: 451-458.
  25. Campo S., Sardo M. A., Bitto A. et al. Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals. Clin. Chem. 2004; 50 (11): 2077-2082.
  26. Packard C. J., O'Reilly D. S. J., Caslake M. J. et al. Lipoprotein-associated phospholipase A2, as an independent predictor of coronary heart disease. N. Eng. J. Med. 2000; 343: 1148- 1155.
  27. Oei H. H., van der Meer I. M., Hofman A. et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005; 111: 570-575.
  28. Титов В. Н. Атеросклероз как патология полиеновых жирных кислот. М.: Алтус; 2002.
  29. Shi Y., Zhang P., Zhang L. et al. Role of lipoprotein-associated phospholipase A2 in leucocyte activation and inflammatory responses. Atherosclersis 2007; 191: 54-62.
  30. Pruzanski W., Vadas P. Phospholipase A2- a mediator between proximal and distal effectors of inflammation. Immunol. Today 1991; 12: 143-146.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies